Par Net Working Capital from 2010 to 2024

PAR Stock   290.40  11.35  4.07%   
Par Drugs' Net Working Capital is increasing over the years with slightly volatile fluctuation. Overall, Net Working Capital is expected to go to about 495.4 M this year. During the period from 2010 to 2024 Par Drugs Net Working Capital annual values regression line had geometric mean of  68,328,229 and mean square error of 8857.6 T. View All Fundamentals
 
Net Working Capital  
First Reported
2010-12-31
Previous Quarter
471.8 M
Current Value
495.4 M
Quarterly Volatility
197.7 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Par Drugs financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Par Drugs' main balance sheet or income statement drivers, such as Depreciation And Amortization of 33.2 M, Total Revenue of 669.2 M or Gross Profit of 640.4 M, as well as many indicators such as . Par financial statements analysis is a perfect complement when working with Par Drugs Valuation or Volatility modules.
  
This module can also supplement various Par Drugs Technical models . Check out the analysis of Par Drugs Correlation against competitors.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Par Stock

Par Drugs financial ratios help investors to determine whether Par Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Par with respect to the benefits of owning Par Drugs security.